ClinicalTrials.gg
CompletedNCT05319912Updated Aug 2, 2023Results posted

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

A Phase 1 interventional study of ALXN1840 Enteric-coated Tablet and ALXN1840 Non-coated Capsule in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 years 11 months after the study started (first participant enrolled Apr 2014, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.

02

Conditions studied

  • Healthy

Keywords

  • ALXN1840
  • WTX101
  • Omeprazole
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoker
  • Medically healthy with no laboratory profiles, vital signs, or .
  • ≥ 18 and ≤ 32.0 kilograms/meter squared.
  • Willing and able to adhere to requirements.

Exclusion criteria

Exclusion Criteria:

  • Participant was mentally or legally incapacitated
  • History or presence of medical or psychiatric condition or disease.
  • History of any illness that might have interfered with drug absorption.
  • History or presence of or idiosyncratic reaction to the study medications, study medication .
  • History or presence of alcoholism or drug abuse.
  • Female participants who were pregnant or lactating.
  • Positive results at screening for , surface antigen, or virus.
  • Serum ceruloplasmin and copper values outside of the normal range at screening.
  • On a diet incompatible with the on-study diet within the 28 days prior to the first ALXN1840 dose and throughout the study; unable to consume the contents of a high-fat breakfast.
  • Participation in a previous clinical trial with ALXN1840.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sequence 1: ABC

    Participants received each treatment on 1 occasion: Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

  • Experimental
    Sequence 2: ACB

    Participants received each treatment on 1 occasion: Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

  • Experimental
    Sequence 3: BAC

    Participants received each treatment on 1 occasion: Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

  • Experimental
    Sequence 4: BCA

    Participants received each treatment on 1 occasion: Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

  • Experimental
    Sequence 5: CAB

    Participants received each treatment on 1 occasion: Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

  • Experimental
    Sequence 6: CBA

    Participants received each treatment on 1 occasion: Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.

    Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole

Interventions

  • ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.

    Also known as: WTX101 (formerly), Bis-choline tetrathiomolybdate, Tiomolibdate choline

  • ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.

    Also known as: WTX101 (formerly), Bis-choline tetrathiomolybdate, Tiomolibdate choline

  • Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.

    Also known as: Prilosec

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)

    AUC0-t was calculated by the linear trapezoidal method.

    Time frame: Predose (0 hour) up to 192 hours postdose

  2. Maximum Measured Plasma Concentration (Cmax) of Total Mo

    Time frame: Predose (0 hour) up to 192 hours postdose

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 through 14 days following final dose (up to Day 43)

07

Results

Posted Aug 2, 2023

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence 1: ABCTreatment Sequence 2: ACBTreatment Sequence 3: BACTreatment Sequence 4: BCATreatment Sequence 5: CABTreatment Sequence 6: CBA
Started333333
Received at least 1 dose of study drug333333
Completed333333
Not completed000000

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)

AUC0-t was calculated by the linear trapezoidal method.

Time frame:
Predose (0 hour) up to 192 hours postdose
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)
hours*ng/mLTreatment A: ALXN1840 (Fasted)Treatment B: ALXN1840 (Fed)Treatment C: Omeprazole + ALXN1840 (Fasted)
Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)16026 ± 56355740 ± 468119809 ± 3509
Statistical analysis
  • Treatment A: ALXN1840 (Fasted) vs Treatment C: Omeprazole + ALXN1840 (Fasted) · Geometric mean ratio (%): 75.81 · 90% CI 52.23 to 110.02
  • Treatment A: ALXN1840 (Fasted) vs Treatment B: ALXN1840 (Fed) · Geometric mean ratio (%): 25.20 · 90% CI 17.21 to 36.89
PrimaryMaximum Measured Plasma Concentration (Cmax) of Total Mo
Time frame:
Predose (0 hour) up to 192 hours postdose
Reported as:
Mean · ng/mL
Maximum Measured Plasma Concentration (Cmax) of Total Mo
ng/mLTreatment A: ALXN1840 (Fasted)Treatment B: ALXN1840 (Fed)Treatment C: Omeprazole + ALXN1840 (Fasted)
Maximum Measured Plasma Concentration (Cmax) of Total Mo376 ± 98.0187 ± 118442 ± 69.6
Statistical analysis
  • Treatment A: ALXN1840 (Fasted) vs Treatment C: Omeprazole + ALXN1840 (Fasted) · Geometric mean ratio (%): 82.65 · 90% CI 63.91 to 106.90
  • Treatment A: ALXN1840 (Fasted) vs Treatment B: ALXN1840 (Fed) · Geometric mean ratio (%): 40.49 · 90% CI 31.12 to 52.68
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 through 14 days following final dose (up to Day 43)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTreatment A: ALXN1840 (Fasted)Treatment B: ALXN1840 (Fed)Treatment C: Omeprazole + ALXN1840 (Fasted)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)426

Adverse events

Collected over Day 1 through 14 days following final dose (up to Day 43). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: ALXN1840 (Fasted)—0/18 (0%)4/18 (22.2%)
Treatment B: ALXN1840 (Fed)—0/18 (0%)2/18 (11.1%)
Treatment C: Omeprazole + ALXN1840 (Fasted)—0/18 (0%)6/18 (33.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatment A: ALXN1840 (Fasted)Treatment B: ALXN1840 (Fed)Treatment C: Omeprazole + ALXN1840 (Fasted)
DysphoniaRespiratory, thoracic and mediastinal disorders0/180/181/18
Nasal congestionRespiratory, thoracic and mediastinal disorders1/181/180/18
Nasal drynessRespiratory, thoracic and mediastinal disorders1/180/180/18
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/180/181/18
Abdominal distensionGastrointestinal disorders0/180/181/18
DiarrhoeaGastrointestinal disorders1/181/180/18
NauseaGastrointestinal disorders0/181/180/18
ContusionInjury, poisoning and procedural complications1/180/180/18
LacerationInjury, poisoning and procedural complications0/180/181/18
HeadacheNervous system disorders1/180/181/18

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: ABCTreatment Sequence 2: ACBTreatment Sequence 3: BACTreatment Sequence 4: BCATreatment Sequence 5: CABTreatment Sequence 6: CBATotal
Mean42.3 ± 15.9533.7 ± 16.0725.7 ± 3.0638.0 ± 13.0040.7 ± 11.3731.7 ± 10.9735.3 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: ABCTreatment Sequence 2: ACBTreatment Sequence 3: BACTreatment Sequence 4: BCATreatment Sequence 5: CABTreatment Sequence 6: CBATotal
Female0002316
Male33310212
08

Study locations

1 site
  • Clinical Trial Site
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in May 2014, 1 month.

Results were first posted in Aug 2023, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 8, 2022
StartActual
Apr 7, 2014
Primary completionActual
May 29, 2014
CompletionActual
May 29, 2014
Results first posted
Aug 2, 2023
Last update
Aug 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05319912
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Apr 7, 2014
Primary completion
May 29, 2014
Completion
May 29, 2014
Results posted
Aug 2, 2023
Last update
Aug 2, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tetrathiomolybdate · Omeprazole

Start the discussion